Study: Targeting specific genomic mutation in breast cancer improves survival

[News]

Targeting a common mutation in patients with hormone receptor positive (HR+) HER2 negative (HER2-) advanced breast cancer with the alpha-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib significantly improves progression-free survival, according to late-breaking results reported at ESMO 2018.

More... (https://www.news-medical.net/news/20181022/Study-Targeting-specific-genomic-mutation-in-breast-cancer-improves-survival.aspx)